Syros Pharmaceuticals, Inc.·4

Feb 14, 4:06 PM ET

Quirk Gerald E 4

4 · Syros Pharmaceuticals, Inc. · Filed Feb 14, 2020

Insider Transaction Report

Form 4
Period: 2020-02-13
Quirk Gerald E
Chief Legal Officer
Transactions
  • Award

    Stock Option (right to buy)

    2020-02-13+94,00094,000 total
    Exercise: $7.54Exp: 2030-02-12Common Stock (94,000 underlying)
Footnotes (1)
  • [F1]This option becomes exercisable as to 25% of the shares on February 28, 2021, with the remainder vesting in equal monthly installments of 2.0833% of the shares underlying the award at the end of each successive month thereafter.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION